<DOC>
	<DOCNO>NCT01460108</DOCNO>
	<brief_summary>The purpose study characterize safety efficacy AeriSeal System patient advance upper lobe predominant emphysema significant collateral ventilation determine Chartis System .</brief_summary>
	<brief_title>AeriSeal System Patients With Advanced Upper Lobe Predominant Emphysema Collateral Ventilation</brief_title>
	<detailed_description>This investigator initiate , open-label , uncontrolled study prospectively characterize safety efficacy AeriSeal System patient advance upper lobe predominant emphysema find significant collateral ventilation use Chartis System .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Willing able provide inform consent participate study Diagnosis advance emphysema ( GOLD Stage III Stage IV disease ) Radiologic evidence nonbullous upper lobe predominant heterogeneous emphysema least 2 target site deem appropriate treatment evident CT image DLco 20 60 % predict Positive Collateral Ventilation determine Chartis® System Clinically significant dyspnea ( define MRC dyspnea score 2 great Screening ) Failure standard medical therapy provide adequate relief symptom ( defined regular use standard medication 1 month prior Screening ; standard medication include least inhaled beta agonist inhale anticholinergic unless medically contraindicate prior medical failure ) Significant airflow obstruction demonstrate Spirometry 15 minute administration bronchodilator : 5 % &lt; FEV1 &lt; 50 % predict use ATS recommend calculation expect value FEV1/FVC ratio &lt; 70 % Physiological evidence hyperinflation Lung volume ( plethysmographic ) : TLC &gt; 100 % predict use ATS recommend calculation expect value RV &gt; 135 % predict use ATS recommend calculation expect value SixMinute Walk Test distance ≥ 150 Abstinence inhale tobacco use least 16 week prior initial Screening visit end study Female patient either postmenopausal surgically sterile . Women childbearing potential include study Alpha1 antitrypsin serum level &lt; 80 mg/dL ( i.e . &lt; 11 micro mol/L ) Screening Body mass index &lt; 15 kg/m2 &gt; 35 kg/m Clinically significant asthma , chronic bronchitis bronchiectasis determine Investigator , significant COPD exacerbation within past 4 month Use systemic steroid &gt; 20 mg/day equivalent immunosuppressive agent , heparin , oral anticoagulant ( e.g. , warfarin , dicumarol ; note : antiplatelet drug include aspirin clopidogrel permit ) investigational medication within 4 week Screening Allergy sensitivity medication require safely perform AeriSeal System treatment general anesthesia conscious sedation Participation investigational study drug , biologic , device currently approve marketing within 30 day prior Screening visit Prior lung volume reduction surgery , prior lobectomy pneumonectomy , prior lung transplantation , prior airway stent placement , prior pleurodesis , prior endobronchial lung volume reduction therapy type Significant comorbidity carry prohibitive risk ( e.g. , HIV/AIDS , cancer ) associate less 2year expect survival Blood gas oxygen saturation : SpO2 ≤ 90 % &gt; 4 L/min supplemental O2 , rest PaCO2 ≥ 55mmHg DLCO &lt; 20 % &gt; 60 % predict patient heterogeneous emphysema Chest CT scan : Presence follow radiologic abnormality : Pulmonary nodule CT scan great 1.0 cm diameter ( Does apply present 2 year without increase size proven benign biopsy/PET ) Giant Bullous Disease Radiologic picture consistent active pulmonary infection , e.g. , unexplained parenchymal infiltrate Significant interstitial lung disease ( base upon investigator judgment ) Significant pleural disease ( base upon investigator judgment ) Any condition Investigator believe would interfere intent study would make participation best interest patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>PLVR</keyword>
	<keyword>AeriSeal</keyword>
	<keyword>Treatment</keyword>
	<keyword>Device</keyword>
	<keyword>Breathing</keyword>
	<keyword>COPD</keyword>
	<keyword>emphysema</keyword>
	<keyword>polymeric lung volume reduction</keyword>
	<keyword>heterogeneous</keyword>
	<keyword>homogeneous</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>